Sinopharm Wuhan for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
Sinopharm Wuhan Vero cell NCT04510207		RCT	Sinopharm Wuhan	placebo	COVID-19 prophylaxis (excluding children)	NA	13765/13765	suggested	suggested 79 % decrease in hospitalization suggested 78 % decrease in symptomatic Covid-19

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis